Ascidian and Lilly signed a collaboration today to use Ascidian's RNA exon editing platform for monogenic kidney diseases, potentially worth up to $1.9 billion in milestones
Ascidian CEO Mike Ehlers tells us about the deal and discusses the technology and the potential benefits of it over DNA editing and other genetic medicine approaches.










.png)